M&A - GoINPHARMA
Tuesday, 16 October 2018 - 19:50

M&A

Allergan sells Rhofade for €65m

US-based Aclaris Therapeutics (Pennsylvania) has acquired global rights to Allergan’s Rhofade. The drug is a cutaneous therapy for the treatment of cutaneous facial erythema, which in 2011 was  included into Allergan’s portfolio following the acquisition of Vicept Therapeutics. (Source: Aclaris)

Bayer considering sale of Animal Health business (€6-7bn)

Werner Baumann, CEO of Germany-based group Bayer, has told in an interview that his company’s management is assessing a sale of the Animal Health division. The segment last year delivered €1.6bn, with a 24% EBITDA. The sale might fetch Bayer…

Stada and Mylan targeting Bristol-Myers Squibb’s Upsa (€1bn)

Germany-based generics producer Stada is reportedly targeting French OTC manufacturer Upsa, owned by Bristol-Myers Squibb. The news has been reported by Reuters, according to which Mylan and France-based Pierre Fabre are targeting the company too. Upsa has 1,500 employees and…

Historic Otsuka-Proteus agreement on new drugs with sensor ($700m)

Historic agreement between Japan-based group Otsuka and Proteus Digital Health: the deal aims to extend the existing collaboration, which has already led to the FDA approval of Abilify Mycite–that is Otsuka Pharmaceutical’s antipsychotic drug Abilify (aripiprazole), including a sensor that…

Breathtec acquires Nash Pharmaceuticals

Canada-based group Breathtec Biomedical has announced it has acquired Nash Pharmaceuticals, another Canadian company with a pipeline of products still undergoing clinical trials in patients with Non-Alcoholic Steatohepatitis (NASH). NASH is a pathology spreading at an increasing rate, especially in the…

Recordati seeks to obtain €500m line of credit for new acquisitions

Italian economic-financial daily Il Sole 24 Ore has reported that drugmaker Recordati, recently acquired by private equity CVC, is seeking to obtain from banks–especially Intesa SanPaolo–a loan of approximately €500m to be used for acquisitions abroad. (Source: Il Sole 24…

Brazil’s EMS seeking to acquire Teva’s Medis

The Brazilian daily O Estado de Sao Paolo has reported today that the local generics manufacturer EMS is targeting Teva’s division Medis, headquartered in Island, that produces generic drugs. EMS is already in talks with banks to obtain a $900m…

Roche strengthens oncology division by acquiring Tusk for €655m

Roche has acquired Belgian biotech Tusk Therapeutics, paid €655m. Tusk has developed its own CAR-T therapy with specific anticarcinogenic properties, which will be developed through clinical trials not sooner than 2019. Tusk was established in 2014 by Droia Oncology Ventures,…

Medtronic acquires Israel-based Mazor Robotics for $1.64bn

  The large medical device producer Medtronic has acquired Israel-based Mazor Robotics for $1.64bn. The deal strengthens Medtronic’s spinal surgery portfolio. The two companies had already been partners since 2016 when they entered the agreement, which entitles Medtronic to be…

Nestlé announces plan to divest Skin Health division ($4.1bn)

Nestlé has announced today that it intends to sell its Skin-Health division, which analysts estimate to be worth at least $4.1bn. The decision is probably due to investors–such as Daniel Loeb–increasingly pressurizing Nestlé into reorganizing the group. The Switzerland-based company…

Nestlé, Unilever and Coca-Cola targeting GSK’s Horlicks ($3bn)

The Financial Times has reported today that the three major FMCG multinationals–Nestlé, Unilever and Coca-Cola–have submitted a bid to GlaxoSmithKline for Horlicks, an Indian manufacturer of malted drinks. The offers are approximately worth $2.5bn-$3bn, the article reports. GSK has allowed…

Teva’s Medis to be sold soon ($500m)

Reuters has reported that Teva’s Medis’ division developing generic drugs on behalf of third parties, headquartered in Island, is drawing interest from private equities. Teva could soon receive the first offers, expected to be of approximately $500m, according to the…

Boehringer Ingelheim acquires biotech Vira Therapeutics for €210m

Germany-based Boehringer Ingelheim yesterday announced the acquisition of Vira Therapeutics for €210m. Vira Therapeutics is a biotech based in Austria, focusing on the research for virus-based therapies for the treatment of cancer.  Vira develops viruses which are then patented. These…

Galapagos opposes takeover attempt by Gilead

Onno van de Stolpe, CEO of Belgium-based biotech Galapagos, has reported to Belgian daily De Tijd that his company won’t be acquired in the near future by US-based Gilead and will, instead,  remain independent. The statement addresses the rumors circulating…

An analysis of Bayer group following integration of Monsanto

The Germany-based economic and financial daily Handelsblatt today has published a long analysis of the Bayer group, as it has consolidated the $63bn acquisition of Bayer. The financial community is skeptical about the added value Monsanto has provided to the…

Eli Lilly expects to raise at least $1.45bn from Elanco IPO

The US-based group Eli Lilly expects to raise at least $1.45bn by listing 20% of its Elanco division (Animal Health business), that is approximately 63 million shares at a price between $20 and $23 per share. The decision to list…

Group of Takeda’s shareholders opposes $62bn acquisition of Shire

Kazu Takedahas, founder of Takeda Pharmaceutical, is opposing the acquisition of Shire and, together with a group of small investors, is trying to block the transaction which, in his opinion, would result in a disaster for the company. The group…

Coca-Cola preparing $4bn offer for GSK’s Horlicks

The British daily The Telegraph yesterday reported that Coca-Cola Co is about to submit a multi-billion offer for GlaxoSmithKline’s Horlicks Ltd. Horlicks is part of GSK group and produces malted energy drinks. It is worth at least $4bn, analysts say….

Boston Scientific acquires Augmenix for $600m

Boston Scientific (Massachusetts) has announced the acquisition of Augmenix, Inc. for $600m. As part of the agreement, Boston Scientific will pay Augmenix an upfront $500m, plus an additional $100m subject to fulfillment of precise milestones. Augmenix is headquartered in Bedford,…

Novartis sells US dermatology unit to Aurobindo for 1 billion dollars

Switzerland-based Novartis yesterday evening announced that it has sold its US dermatology unit to Aurobindo Pharma for $900m. The deal includes an additional payment of $100m of potential earn-outs, based on successful completion of precise milestones. The divested unit is…

Emergent BioSolutions acquires Adapt Pharma (Narcan) for $735m

Emergent BioSolutions announced today, before Wall Street opened, that it acquired Ireland-based Adapt Pharma for $735m. Adapt’s leading brand is Narcan Nasal Spray (naloxone HCl), the only non-intravenous form of Naloxone ever approved by FDA. It is indicated for opioid…

Green light in EU to sale of Merck KGaA’s OTC division to P&G

Germany-based Merck KGaA has obtained by the European Union competition watchdogs the authorization to sell its OTC division to P&G for €3.4bn. The transaction was announced as early as last April. Specifically, the German company will sell a part of…

Advent International exploring sale of Mediq

Private equity Advent International is reportedly considering a sale of its Netherlands-based subsidiary Mediq, Dutch economic and financial daily Het Financieele Dagblad has reported. Mediq was established in 1889 and employs approximately 3,000 people, producing and marketing pharmaceutical products and…

Gilead sells investigational therapy momelotinib to Sierra Oncology for $198m

Canada-based biotech Sierra Oncology has announced it has acquired momelotinib, an investigational therapy for the treatment of myelofibrosis developed by California-based Gilead Sciences. The deal includes an upfront $3m payment by Sierra, plus additional  payments based on successful completion of…

European watchdog approves Linde-Praxair merger

The European watchdog today has approved the $80bn merger between Germany-based Linde and its US-based competitor Praxair. The approval has been granted as companies have sold Praxair’s European assets to Japan-based Taiyo Nippon Sanso for €5bn and have transferred the…